Acquisition History Blockade Medical was acquired by Balt International in 2016, signaling a potential continuation of integration with larger medtech ecosystems and opportunities to align sales efforts with Balt’s distribution and channel partners.

Niche Focus Specializes in catheter-based neurovascular devices for cerebral aneurysm treatment, presenting a targeted upsell or cross-sell opportunity with other neurovascular portfolios and hospitals seeking advanced interventional solutions.

Early Stage Revenue Current revenue range is modest ($1M-$10M) with a relatively small team, indicating a high-growth startup profile where strategic partnerships and pilot programs could yield significant returns.

Regional Footprint Headquartered and predominantly designed and manufactured in California, suggesting a strong regional sales focus with potential to leverage West Coast academic medical centers and medtech hubs for trials and early adoption.

Competitive Benchmark Among peers, Blockade Medical sits between small nimble players and large incumbents; opportunities exist to position complementary value against larger rivals like Penumbra and Stryker through targeted clinical efficacy propositions and integrated support packages.